JP Morgan Chase
IMVT icon

JP Morgan Chase’s Immunovant IMVT Stock Holding History

JP Morgan Chase’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-216,500
Closed -$8.31M – 7684
2023
Q3 		$8.31M Buy
+216,500
New +$4.89M ﹤0.01% 2410

Other funds holding IMVT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

JP Morgan Chase's IMVT Position: Q2 2026 in Review

JP Morgan Chase reduced its Immunovant (IMVT) stake by 32% in Q2 2026, selling an estimated $935K and leaving 66,186 shares worth $2.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3963.

JP Morgan Chase first reported a position in IMVT in Q1 2020 and has held it in 26 quarters since. The position peaked at $28.6M in Q4 2024. 127 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • JP Morgan Chase held 66,186 shares of Immunovant worth $2.7M as of Q2 2026.
  • JP Morgan Chase sold 30,696 Immunovant shares in Q2 2026, an estimated $935K.
  • Immunovant made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3963 holding.
  • JP Morgan Chase first reported a position in Immunovant in Q1 2020 and has held it in 26 quarters since.
  • JP Morgan Chase's Immunovant position peaked at $28.6M in Q4 2024.
  • 127 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.